The fibrotic microenvironment as a heterogeneity facet of hepatocellular carcinoma

Fibrogenesis and Tissue Repair

Volumn 6, Issue 1, 2013, Pages

  Rombouts, Krista ^a   Carloni, Vinicio ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Activated hepatic stellate cells (HSC); Integrins; Intra tumor heterogeneity; Liver cancer; Tetraspanin enriched microdomains

Indexed keywords

ADAM PROTEIN; CD151 ANTIGEN; CD81 ANTIGEN; DISINTEGRIN; MEMBRANE PROTEIN; PROTEOME; TETRASPANIN;

CELL MEMBRANE; EPIGENETICS; EXTRACELLULAR MATRIX; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PHENOTYPIC VARIATION; PROTEIN LOCALIZATION; REVIEW; STELLATE CELL; TUMOR MICROENVIRONMENT;

EID: 84886928809     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-6-17     Document Type: Review

References (57)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011, 365:1118-1127. 10.1056/NEJMra1001683, 21992124.
2. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006, 6:674-687. 10.1038/nrc1934, 16929323.
3. Li Y, Tang ZY, Hou JX. Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol 2012, 9:32-43.
4. Tao Y, Ruan J, Yeh SH, Lu X, Wang Y, Zhai W, Cai J, Ling S, Gong Q, Chong Z, Qu Z, Li Q, Liu J, Yang J, Zheng C, Zeng C, Wang HY, Zhang J, Wang SH, Hao L, Dong L, Li W, Sun M, Zou W, Yu C, Li C, Liu G, Jiang L, Xu J, Huang H, et al. Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A 2011, 108:12042-12047. 10.1073/pnas.1108715108, 3141952, 21730188.
5. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010, 103:1139-1143. 10.1038/sj.bjc.6605912, 2967073, 20877357.
6. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837. 10.1016/j.cell.2009.02.024, 2894612, 19269363.
7. Brock A, Chang H, Huang S. Non-genetic heterogeneity a mutation-independent driving force for the somatic evolution of tumours. Nat Rev Genet 2009, 10:336-342. 10.1038/nrg2556, 19337290.
8. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer?. Nat Rev Cancer 2012, 12:323-334.
9. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Pierre Martinez P, Matthews N, Stewart A. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892. 10.1056/NEJMoa1113205, 22397650.
10. Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, Downward J, Szallasi Z, Tomlinson IP, Howell M, Kschischo M, Swanton C. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 2011, 71:1858-1870. 10.1158/0008-5472.CAN-10-3604, 3059493, 21363922.
11. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 2010, 18:884-901. 10.1016/j.devcel.2010.05.012, 2905377, 20627072.
12. Bissell MJ, Kenny PA, Radisky DC. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol 2005, 70:343-356. 10.1101/sqb.2005.70.013, 3004779, 16869771.
13. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006, 1:119-150. 10.1146/annurev.pathol.1.110304.100224, 18039110.
14. Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, Travali S, Spandidos DA, Libra M. The tumour microenvironment in hepatocellular carcinoma. Int J Oncol 2012, 40:1733-1747.
15. Wu SD, Ma YS, Fang Y, Liu LL, Fu D, Shen XZ. Role of the microenvironment in hepatocellular carcinoma development and progression. Cancer Treat Rev 2012, 38:218-225. 10.1016/j.ctrv.2011.06.010, 21763074.
16. Mikula M, Proell V, Fischer AN, Mikulits W. Activated hepatic stellate cells induce tumor progression of neoplastic hepatocytes in a TGF-beta dependent fashion. J Cell Physiol 2006, 209:560-567. 10.1002/jcp.20772, 2900580, 16883581.
17. Coulouarn C, Corlu A, Glaise D, Guénon I, Thorgeirsson SS, Clément B. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res 2012, 72:2533-2542. 10.1158/0008-5472.CAN-11-3317, 3498759, 22419664.
18. Zhao W, Zhang L, Yin Z, Su W, Ren G, Zhou C, You J, Fan J, Wang X. Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. Int J Cancer 2011, 129:2651-2661. 10.1002/ijc.25920, 21213212.
19. Sancho-Bru P, Juez E, Moreno M, Khurdayan V, Morales-Ruiz M, Colmenero J, Arroyo V, Brenner DA, Ginès P, Bataller R. Hepatocarcinoma cells stimulate the growth, migration and expression of pro-angiogenic genes in human hepatic stellate cells. Liver Int 2010, 30:31-41. 10.1111/j.1478-3231.2009.02161.x, 19929904.
20. Faouzi S, Lepreux S, Bedin C, Dubuisson L, Balabaud C, Bioulac-Sage P, Desmoulière A, Rosenbaum J. Activation of cultured rat hepatic stellate cells by tumoral hepatocytes. Lab Invest 1999, 79:485-493.
21. Xia Y, Chen R, Song Z, Ye S, Sun R, Xue Q, Zhang Z. Gene expression profiles during activation of cultured rat hepatic stellate cells by tumoral hepatocytes and fetal bovine serum. J Cancer Res Clin Oncol 2010, 136:309-321. 10.1007/s00432-009-0666-5, 19727817.
22. Garcia MG, Bayo J, Bolontrade MF, Sganga L, Malvicini M, Alaniz L, Aquino JB, Fiore E, Rizzo MM, Rodriguez A, Lorenti A, Andriani O, Podhajcer O, Mazzolini G. Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo. Mol Pharm 2011, 8:1538-1548. 10.1021/mp200137c, 21770423.
23. Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC, Odell MM, Bauer RL, Ren HP, Haugen HS, Yeh MM, Fausto N. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci U S A 2005, 102:3389-3394. 10.1073/pnas.0409722102, 552940, 15728360.
24. Hou X, Kumar A, Lee C, Wang B, Arjunan P, Dong L, Maminishkis A, Tang Z, Li Y, Zhang F, Zhang SZ, Wardega P, Chakrabarty S, Liu B, Wu Z, Colosi P, Fariss RN, Lennartsson J, Nussenblatt R, Gutkind JS, Cao Y, Li X. PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets. Proc Natl Acad Sci U S A 2010, 107:12216-12221. 10.1073/pnas.1004143107, 2901428, 20566880.
25. Nevzorova YA, Hu W, Cubero FJ, Haas U, Freimuth J, Tacke F, Trautwein C, Liedtke C. Overexpression of c-myc in hepatocytes promotes activation of hepatic stellate cells and facilitates the onset of liver fibrosis. Biochim Biophys Acta 1832, 2013:1765-1775.
26. van Zijl F, Mair M, Csiszar A, Schneller D, Zulehner G, Huber H, Eferl R, Beug H, Dolznig H, Mikulits W. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 2009, 28:4022-4033. 10.1038/onc.2009.253, 2900602, 19718050.
27. Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Osterreicher CH, Kodama Y, Miura K, Ikai I, Uemoto S, Brenner DA. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 2008, 135:1729-1738. 10.1053/j.gastro.2008.07.065, 18823985.
28. Campbell JS, Johnson MM, Bauer RL, Hudkins KL, Gilbertson DG, Riehle KJ, Yeh MM, Alpers CE, Fausto N. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. Differentiation 2007, 75:843-852. 10.1111/j.1432-0436.2007.00235.x, 17999742.
29. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000, 1:31-39. 10.1038/35036052, 11413487.
30. Gao X, Lowry PR, Zhou X, Depry C, Wei Z, Wong GW, Zhang J. PI3K/Akt signaling requires spatial compartmentalization in plasma membrane microdomains. Proc Natl Acad Sci U S A 2011, 108:14509-14514. 10.1073/pnas.1019386108, 3167518, 21873248.
31. Yáñez-Mó M, Barreiro O, Gordon-Alonso M, Sala-Valdés M, Sánchez-Madrid F. Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. Trends Cell Biol 2009, 19:434-446. 10.1016/j.tcb.2009.06.004, 19709882.
32. Mazzocca A, Carloni V, Sciammetta S, Cordella C, Pantaleo P, Caldini A, Gentilini P, Pinzani M. Expression of transmembrane 4 superfamily (TM4SF) proteins and their role in hepatic stellate cell motility and wound healing migration. J Hepatol 2002, 37:322-330. 10.1016/S0168-8278(02)00175-7, 12175627.
33. Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer 2009, 9:40-55. 10.1038/nrc2543, 19078974.
34. Oren R, Takahashi S, Doss C, Levy R, Levy S. TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol 1990, 10:4007-4015. 360911, 1695320.
35. Carloni V, Mazzocca A, Ravichandran KS. Tetraspanin CD81 is linked to ERK/MAPKinase signaling by Shc in liver tumor cells. Oncogene 2004, 23:1566-1574. 10.1038/sj.onc.1207287, 14676841.
36. Mukherjee S, Maxfield FR. Membrane domains. Annu Rev Cell Dev Biol 2004, 20:839-866. 10.1146/annurev.cellbio.20.010403.095451, 15473862.
37. Inoue G, Horiike N, Onji M. The CD81 expression in liver in hepatocellular carcinoma. Int J Mol Med 2001, 7:67-71.
38. Schöniger-Hekele M, Hänel S, Wrba F, Müller C. Hepatocellular carcinoma-survival and clinical characteristics in relation to various histologic molecular markers in Western patients. Liver Int 2005, 25:62-69. 10.1111/j.1478-3231.2004.0997.x, 15698400.
39. Mazzocca A, Liotta F, Carloni V. Tetraspanin CD81-regulated cell motility plays a critical role in intrahepatic metastasis of hepatocellular carcinoma. Gastroenterology 2008, 135:244-256. 10.1053/j.gastro.2008.03.024, 18466772.
40. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med 2008, 359:2814-2823. 10.1056/NEJMra0805239, 19109576.
41. Testa JE, Brooks PC, Lin JM, Quigley JP. Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Cancer Res 1999, 59:3812-3820.
42. Ke AW, Shi GM, Zhou J, Huang XY, Shi YH, Ding ZB, Wang XY, Devbhandari RP, Fan J. CD151 amplifies signaling by integrin α6β1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Gastroenterology 2011, 140:1629-1641. 10.1053/j.gastro.2011.02.008, 21320503.
43. Gesierich S, Berezovskiy I, Ryschich E, Zoller M. Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029. Cancer Res 2006, 66:7083-7094. 10.1158/0008-5472.CAN-06-0391, 16849554.
44. Kanetaka K, Sakamoto M, Yamamoto Y, Takamura M, Kanematsu T, Hirohashi S. Possible involvement of tetraspanin CO-029 in hematogenous intrahepatic metastasis of liver cancer cells. J Gastroenterol Hepatol 2003, 18:1309-1314. 10.1046/j.1440-1746.2003.03182.x, 14535989.
45. Guo XZ, Friess H, Di Mola FF, Heinicke JM, Abou-Shady M, Graber HU, Baer HU, Zimmermann A, Korc M, Büchler MW. KAI1, a new metastasis suppressor gene, is reduced in metastatic hepatocellular carcinoma. Hepatology 1998, 28:1481-1488. 10.1002/hep.510280606, 9828210.
46. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004, 5:816-826. 10.1038/nrm1490, 15459662.
47. Begum NA, Mori M, Matsumata T, Takenaka K, Sugimachi K, Barnard GF. Differential display and integrin alpha 6 messenger RNA overexpression in hepatocellular carcinoma. Hepatology 1995, 22:1447-1455.
48. Torimura T, Ueno T, Kin M, Inuzuka S, Sugawara H, Tamaki S, Tsuji R, Sujaku K, Sata M, Tanikawa K. Coordinated expression of integrin alpha6beta1 and laminin in hepatocellular carcinoma. Hum Pathol 1997, 28:1131-1138. 10.1016/S0046-8177(97)90250-1, 9343319.
49. Wewer UM, Shaw LM, Albrechtsen R, Mercurio AM. The integrin alpha 6 beta 1 promotes the survival of metastatic human breast carcinoma cells in mice. Am J Pathol 1997, 151:1191-1198. 1858063, 9358743.
50. Nejjari M, Hafdi Z, Dumortier J, Bringuier AF, Feldmann G, Scoazec JY. alpha6beta1 integrin expression in hepatocarcinoma cells: regulation and role in cell adhesion and migration. Int J Cancer 1999, 83:518-525. 10.1002/(SICI)1097-0215(19991112)83:4<518::AID-IJC14>3.0.CO;2-Q, 10508489.
51. Carloni V, Romanelli RG, Mercurio AM, Pinzani M, Laffi G, Cotrozzi G, Gentilini P. Knockout of alpha6 beta1-integrin expression reverses the transformed phenotype of hepatocarcinoma cells. Gastroenterology 1998, 115:433-442. 10.1016/S0016-5085(98)70210-0, 9679049.
52. Carloni V, Mazzocca A, Pantaleo P, Cordella C, Laffi G, Gentilini P. The integrin, alpha6beta1, is necessary for the matrix-dependent activation of FAK and MAP kinase and the migration of human hepatocarcinoma cells. Hepatology 2001, 34:42-49.
53. Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 2005, 129:1375-1383. 10.1053/j.gastro.2005.09.055, 16285938.
54. Radisky DC, Bissell MJ. Matrix metalloproteinase-induced genomic instability. Curr Opin Genet Dev 2006, 16:45-50. 10.1016/j.gde.2005.12.011, 2933219, 16377172.
55. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008, 359:1995-2004. 10.1056/NEJMoa0804525, 2963075, 18923165.
56. Kohga K, Takehara T, Tatsumi T, Miyagi T, Ishida H, Ohkawa K, Kanto T, Hiramatsu N, Hayashi N. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Cancer Res 2009, 69:8050-8057. 10.1158/0008-5472.CAN-09-0789, 19826051.
57. Yang CL, Jiang FQ, Xu F, Jiang GX. ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma. Tumour Biol 2012, 33:1535-1541. 10.1007/s13277-012-0405-4, 22581584.